Journal: PLOS One

Article Title: CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity

doi: 10.1371/journal.pone.0321622

Figure Lengend Snippet: Immunocompromised NCG mice were inoculated with A , ANBL-6, B , LP-1, C , MM1.S, or D , JJN-3 tumor cells, at cell numbers outlined in the Materials and Methods section. When tumors reached an average volume of ~ 100 mm 3 (day 0), mice were randomized into treatment groups and treated via intraperitoneal injection with vehicle or 10 mg/kg hCD38-hAtt twice weekly for up to six doses. Tumor volumes were measured twice weekly until humane endpoint was reached. E, Tabulated data summary of CD38 and IFNAR2 expression (mean fluorescence intensity) of each tumor cell line, as measured by flow cytometry.

Article Snippet: Anti-murine CD38-murine Attenukine TM (mCD38-mAtt) was generated by cloning the mAtt fused to an anti-mouse CD38-specific antibody (generated internally at Takeda in a hybridoma campaign) into Expi293 cells (WuXi Biologics).

Techniques: Injection, Expressing, Fluorescence, Flow Cytometry